Document is current
Any future updates will be listed below
-
Authors
Kigar, Stacey L. https://orcid.org/0000-0003-2636-0648
Lynall, Mary-Ellen https://orcid.org/0000-0002-1939-7525
DePuyt, Allison E.
Atkinson, Robert
Sun, Virginia H. https://orcid.org/0000-0003-1387-2994
Samuels, Joshua D.
Eassa, Nicole E.
Poffenberger, Chelsie N.
Lehmann, Michael L.
Listwak, Samuel J.
Livak, Ferenc
Elkahloun, Abdel G.
Clatworthy, Menna R. https://orcid.org/0000-0002-3340-9828
Bullmore, Edward T.
Herkenham, Miles
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (ZIA MH001090, ZIA MH001090, ZIA MH001090, ZIA MH001090, ZIA MH001090, ZIA MH001090, ZIA MH001090, ZIA MH001090, ZIA MH001090, ZIA MH001090)
DH | NIHR | Programme Grants for Applied Research (NIHR203312)
RCUK | Medical Research Council (MR/S006257/1, MR/Z50354X/1)
- License Information
-
More Information
Article History
Received: 3 September 2024
Accepted: 25 July 2025
First Online: 1 September 2025
Competing interests
: The authors declare the following competing interests: E.T.B. has recently consulted Boehringer Ingelheim, SR One, Novartis, GlaxoSmithKline, Sosei Heptares, and Monument Therapeutics. E.T.B. holds equity in and is a cofounder of Centile Bioscience Inc. M.L.L. is currently employed at AstraZeneca but was an employee at NIH at the time this work was conducted. The remaining authors declare no competing interests.
